UNSPSC 51361923: Thiotetrabarbital

This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1P93TO196Z. European Medicines Agency schedules Thiotetrabarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10986MIG. Thiotetrabarbital generally arises in the molecular formula C12H20N2O2S.

UNSPSC 51361923 Thiotetrabarbital is a Commodity code nominally identifying a specific barbiturate pharmaceutical, but recent state and local procurement activity under this code shows little direct relevance to the code's abstract scope. Instead, the opportunities posted against this code reflect broader pharmaceutical procurement covering naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. The mismatch suggests either tagging error in the source system or that this code serves as a catch-all placeholder for pharmaceutical acquisitions that do not fit narrower commodity classifications. State and local issuers soliciting under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states and localities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Recent activity spans Florida, Texas, and the MMCAP multi-state network including Minnesota and Oregon. Seminole County issued IFB 60459723LAS on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023 (note: deadline appears incorrectly backdated in source); delivery is required quarterly to the Seminole County Community Health Building in Sanford, Florida, with a two-year initial term and one-year renewal option. Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed to inform subsequent formal procurement strategy. Minnesota's MMCAP posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026 and contract effective date of July 1, 2026; pricing evaluation weighs price competitiveness at 75 percent, with fixed pricing, administrative compliance, EDI capability, and administrative-fee agreement weighted at 10, 5, 5, and 5 percent respectively. The code shows no recent opportunities showing clear alignment with thiotetrabarbital specifically.